Donald J. Hayden, Jr. Sells 15,000 Shares of Insmed, Inc. (INSM) Stock

Insmed, Inc. (NASDAQ:INSM) Director Donald J. Hayden, Jr. sold 15,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $32.50, for a total value of $487,500.00. Following the transaction, the director now directly owns 71,131 shares in the company, valued at $2,311,757.50. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of Insmed, Inc. (NASDAQ:INSM) traded up $1.28 during mid-day trading on Thursday, hitting $31.34. The stock had a trading volume of 776,800 shares, compared to its average volume of 687,784. The company has a current ratio of 15.21, a quick ratio of 15.21 and a debt-to-equity ratio of 0.13. Insmed, Inc. has a fifty-two week low of $11.49 and a fifty-two week high of $32.94.

WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/16/donald-j-hayden-jr-sells-15000-shares-of-insmed-inc-insm-stock.html.

INSM has been the topic of several recent analyst reports. Leerink Swann upped their target price on Insmed from $27.00 to $36.00 and gave the company an “outperform” rating in a research report on Tuesday, September 5th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Insmed in a research report on Monday, November 6th. Cowen and Company reaffirmed a “buy” rating and set a $54.00 target price on shares of Insmed in a research report on Friday, November 3rd. BidaskClub lowered Insmed from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, ValuEngine lowered Insmed from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Insmed currently has a consensus rating of “Hold” and an average price target of $34.50.

Several hedge funds have recently made changes to their positions in INSM. Parametric Portfolio Associates LLC increased its holdings in shares of Insmed by 39.2% in the first quarter. Parametric Portfolio Associates LLC now owns 14,417 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 4,063 shares during the period. Vanguard Group Inc. increased its holdings in shares of Insmed by 4.8% in the first quarter. Vanguard Group Inc. now owns 3,781,483 shares of the biopharmaceutical company’s stock valued at $66,214,000 after purchasing an additional 173,532 shares during the period. Geode Capital Management LLC increased its holdings in shares of Insmed by 4.7% in the first quarter. Geode Capital Management LLC now owns 493,181 shares of the biopharmaceutical company’s stock valued at $8,635,000 after purchasing an additional 22,345 shares during the period. Morgan Stanley increased its holdings in shares of Insmed by 2.7% in the first quarter. Morgan Stanley now owns 545,514 shares of the biopharmaceutical company’s stock valued at $9,552,000 after purchasing an additional 14,412 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of Insmed by 6.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 283,167 shares of the biopharmaceutical company’s stock valued at $4,959,000 after purchasing an additional 18,331 shares during the period. 74.26% of the stock is currently owned by institutional investors and hedge funds.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply